BMO Capital on Y-mAbs Therapeutics (YMAB): 'Radiopharma Is Hot & SADA De-Risking Would Unlock Value'

BMO Capital analyst Etzer Darout reiterated an Outperform rating and $26.00 price target on Y-mAbs Therapeutics (NASDAQ: YMAB)

The analyst comments "We hosted YMAB's CEO, CFO, and Founder and CBO for a group lunch where the conversation was predominantly focused on the SADA platform as we head toward upcoming data (Phase 1 Part A data readout for GD2-SADA asset in 2H) that start to inform us on the potential for the platform to address the limitations of current radiopharmaceuticals. This class of drugs continues to see strategic interest, and we believe clinical de-risking of SADA could lead to significant value creation for YMAB. Reiterate OP rating."

For an analyst ratings summary and ratings history on Y-mAbs Therapeutics click here. For more ratings news on Y-mAbs Therapeutics click here.

Shares of Y-mAbs Therapeutics closed at $14.56 yesterday.

You May Also Be Interested In

• BMO Capital Reiterates Outperform Rating on Netflix (NFLX), Advertising Seen As a Key Lever
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
• McGraw Hill (MH) PT Raised to $15 at UBS